Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Intelligence Hub
News
Changes
Search
Log in
Get Started
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
NDA
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE | N219616 | VERASTEM INC
1 strength
7 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
VA FSS
Approvals
Label
Products
Patent Timeline
7 unique patents, 2 exclusivities by expiration date
Expiring < 1yr (1)
Active (6)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
Today
7897792
Feb. 9, 2027
7928109
Aug. 21, 2029
8247411
Apr. 17, 2028
11400090
Oct. 29, 2038
11517573
Sep. 11, 2040
11873296
Dec. 29, 2042
12509450
Dec. 29, 2042
NCE
May. 8, 2030
ODE-525
May. 8, 2032
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 0.8MG BASE;EQ 200MG BASE
RLD
7 patents
2 exclusivities
▴
CAPSULE, TABLET;ORAL | Approved: May 8, 2025
Patents (7)
· 4 use codes
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7897792
Feb 9, 2027
—
Yes
Yes
—
—
7928109
Aug 21, 2029
—
Yes
Yes
—
—
8247411
Apr 17, 2028
—
Yes
Yes
—
—
11400090
Oct 29, 2038
—
—
—
U-4196
TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH DEFACTINIB
—
11517573
Sep 11, 2040
—
—
—
U-4196
TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH DEFACTINIB
U-4205
TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH AVUTOMETINIB
—
11873296
Dec 29, 2042
—
—
Yes
U-4196
TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH DEFACTINIB
—
12509450
Dec 29, 2042
—
—
Yes
—
—
Exclusivities (2)
Code
Date
Status
NCE
May 8, 2030
Active
ODE-525
May 8, 2032
Active